Welcome to the

Our Goal: To become a Top 3 BioHealth Hub by 2023

www.biohealthcapital.com
Top 10 U.S. Biopharma Clusters

Ranking Based on Five Criteria: 2019

1. NIH Funding
2. Venture Capital Funding
3. Patents
4. Lab Space
5. Jobs

1. Boston / Cambridge, MA
2. San Francisco Bay Area
3. New York/New Jersey
4. Maryland / Virginia / DC Metro
5. San Diego
6. Greater Philadelphia
7. Los Angeles / Orange County
8. Raleigh-Durham, NC (inc. Research Triangle Park, NC)
9. Seattle
10. Chicagoland

Brand name = BioHealth Capital Region
The Maryland/Virginia/Washington, DC “BioHealth Capital Region (BHCR)” has won over numerous employers as it strives to grow into a top-three cluster by 2023. Kite, a Gilead Company, chose Maryland’s Frederick County to build a 279,000-square-foot manufacturing site for CAR-T therapies, including its marketed Yescarta® (axicabtagene ciloleucel). Also in April, Paragon Bioservices (since acquired by Catalent) opened a 151,000-square-foot commercial manufacturing center in Harmans, MD. AveXis, a Novartis Company, agreed to use Harmans as a manufacturing site for recently-approved gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A month later, Gaithersburg, MD-based Viela Bio filed for a $150 million IPO; the company spun out last year from AstraZeneca, a regional anchor since 2007 when it acquired MedImmune (a name retired in February). French diagnostics developer HalioDx, a Qiagen spinout, opened its first North American lab in Richmond at Virginia Bio+Tech Park, which is partnering with Activation Capital to develop additional space for expansion-stage companies.

Regional anchors also include the NIH, FDA, and Johns Hopkins University, which won 40% ($648.971 million) of the region’s $1.6 billion (3,272 awards) in NIH extramural funding, ranking it third; the agency also devotes about 10% of its $39.234 billion FY 2019 budget to intramural research. BHCR is third in NIH funding (3,272 deals totaling $1.608 billion) and patents (5,367), and fourth in lab space with 22.8 million square feet according to Rockville, MD-based Scheer Partners, which measures the entire region [JLL counts 12.95 million for Northern Virginia/Suburban Maryland/Baltimore). In VC, JLL records $1.229 billion, good for fifth (and better than the $750 million counted by PwC/CB Insights). BHCR’s 55,882 jobs (JLL) ranks the region sixth.
The Growth of the “BioHealth” Brand

BioHealth Innovation

BioHealth Capital Region

Office of Biohealth – Maryland Department of Commerce

BioHealth Capital Region – Genetic Engineering News

Institute for Biohealth Innovation – George Mason

AURP Biohealth Caucus

Wisconsin’s Biohealth Industry

Women in Biohealth – U.W. Madison

Growing Biohealth Cluster – Ohio

Luxembourg Biohealth Cluster

South Korea Biohealth Industry

HIG BioHealth Fund

IT ALL STARTED HERE!

TOP 3 BY 2023
Regional BioHealth Ecosystem Partners

ACADEMIA
- Research/T2
- Lifelong Learning
- Economic Development

INDUSTRY
- Profit
- Process
- Product

GOVERNMENT
- Sustainability
- Infrastructure Support
- Economic Policy

FOUNDATIONS/NGOS
- Economic Growth
- Community Investment
- Regional Collaboration

INSEPARABLE MISSIONS
BHCR Support Organizations

BioHealth Innovation
Richard A. Bendis
President/CEO

"BHI sources and evaluates market-relevant biohealth intellectual properties, connects the IP with funding, and assists businesses in marketing and growth."

Maryland Tech Council
Marty Rosendale
CEO

“We are a collaborative community that is actively engaged in building strong technology and life science industries by supporting the efforts of our individual members.”

Children’s National
Kolaleh Eskandanian, PhD, MBA, PMP®
Vice President and Chief Innovation Office

With a health care experience designed around kids’ unique needs, we’re the premier provider of pediatric services in the Washington, D.C., metro area and its only health system specializing in kids.

TEDCO
Linda Singh
Interim Executive Director & CEO

“TEDCO provides framework of knowledge, funding, and networking to support an innovation eco-system that nurtures researchers, entrepreneurs, start-ups, and early stage companies engaged in bringing innovation ideas to market.”

Virginia Bio
John Newby
CEO

“We fuel the network of leaders that drive bioscience to eradicate disease, save lives, and feed the world…..one innovation at a time.”
State of Maryland: Federal & University Resources

- Population: 5.9 million people
- 78 Federal Laboratories, Centers, & Institutes in Maryland
- Maryland Federal R&D investment exceeding $16 billion annually

JHU and USM represent another $3.8 billion in annual R&D
BioHealth Capital FUND

An Overview of the BHCR – Where You Should Be

- **Top-Tier Research Universities**
  Including Johns Hopkins and the University System of Maryland provide a pipeline of talent & intellectual property

- **78 National Labs & Research Institutes**
  Including NIH, ARL, NRL, and NASA Goddard that receive $16 billion annually and provide technical talent and a pipeline of tested, commercializable technologies

- **Regulatory & Governmental Bodies**
  Including FDA, CMS, and HHS provide thought leadership in the ecosystem and insight into what changes are next

- **Concentration of Science & Engineering Talent**
  From universities, national labs, and government positions with the technical skills to launch high-tech startups, especially with licensed intellectual property

- **Established Cluster of BioHealth Companies**
  Over 2,300 BioHealth companies in BHCR from multinational corporations to cutting edge startups
While ranked 4th nationally in extramural research, the region leads when combined with NIH’s intramural research, which has over $4 billion of funding per year and is conducted by nearly 6,000 scientists primarily in Bethesda, MD.

Source: JLL Research
Biohealth Asking Rents

Suburban Maryland and the region offer competitive rates for life sciences space when compared against other top-tier biohealth clusters.

Source: JLL Research
Vacancy in Suburban Maryland has stabilized at record low levels.

Source: JLL Research
Unrivaled Research Assets
Unfulfilled Commercial Promise
800+ BioHealth Companies
Public BioHealth Companies Headquartered in the Region

- altimmune
- CEL SCI
- emergent biosolutions®
- GenVec
- GlycoMimetics, Inc.
- INTREXON
- MACROGENICS
- MaxCyte
- NEURALSTEM INC
- NextCure
- NORTHWEST BIOOTHERAPEUTICS
- NOVAVAX
- Osiris Therapeutics, Inc.
- REGENXBIO
- rexahn
- Sucampo
- Supernus Pharmaceuticals
University Progress

- USM and JHU have had over 52 life science startups in last 18 months, many receiving venture capital, 4.0 billion in research expenditures, 104 licenses executed, $60 million in license income, 1208 patent applications filed, 258 Patent’s issued

- USM has created a new $25 million momentum venture fund

- VA Tech establishing a new campus on the Children’s National Walter Reed eco system.

- UVA entered into partnership with Inova to create a Northern Virginia research and education campus

- George Mason has created the BioHealth Innovation Department
Regional Initiatives

• Many independent regional initiatives highlighted in this Forum and for first time communication with each other

• Maryland Life Science Advisory Board implementing recommendations for Governor Hogan

• Connected DMV COVID-19 Strategic Task Force was created by Greater Washington Board of Trade

• MTC Merger Completed

• MCEDC and WorkSource Montgomery two private public partnerships operational
### Challenges to Innovation Economy

- Lack of connection of innovation resources
- Lack of an entrepreneurial culture and C-level executives
- Lack of early-stage funding for commercializing technologies
- Lack of spin-offs from federal and university R&D

### BHI Value Proposition

- Connect regional innovation assets
- Develop an entrepreneurial talent and support pipeline
- Attract funding for technology commercialization
- Evaluate commercially relevant federal and university technology
BioHealth Innovation is a Regional Innovation Intermediary

A public-private partnership, serving as an innovation intermediary in the BioHealth Capital Region with a mission to:

- Advance local technologies, assets and resources
- Accelerate innovation
- Globally connect sectors, industries, communities, and markets

- Regionally-oriented
- Private-public partnership, 501(c)(3) nonprofit
- BioHealth Innovation Management, a for-profit subsidiary
- Market-driven, private sector-led and funded
- Neither a government initiative, nor a membership organization
# BHI Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Role</th>
<th>Company/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Augerson</td>
<td>Vice President</td>
<td>Qiagen</td>
</tr>
<tr>
<td>Richard A. Bendis</td>
<td>President &amp; CEO</td>
<td>BioHealth Innovation, Inc.</td>
</tr>
<tr>
<td>Jarrod Borkat (Chair)</td>
<td>Vice President, Corporate Strategy</td>
<td>Emergent BioSolutions</td>
</tr>
<tr>
<td>Pete Briskman</td>
<td>Managing Director, Jones Lang LaSalle</td>
<td>JLL</td>
</tr>
<tr>
<td>Kenneth Carter, Ph.D.</td>
<td>Chairman</td>
<td>Noble Life Sciences</td>
</tr>
<tr>
<td>Christopher Callaghan</td>
<td>Group Vice President, Healthcare Banking, M&amp;T Bank</td>
<td>M&amp;T Bank</td>
</tr>
<tr>
<td>Ronald J. Daniels</td>
<td>President</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>Rebecca Farkas</td>
<td>Director, External R&amp;D, Scientific Collaborations, GSK</td>
<td>GSK</td>
</tr>
<tr>
<td>William Hearn</td>
<td>Founder &amp; CEO</td>
<td>Immunomic Therapeutics, Inc.</td>
</tr>
<tr>
<td>Juergen Klenk</td>
<td>Principal</td>
<td>Deloitte Consulting, LLP</td>
</tr>
<tr>
<td>Dave Lemus (Treasurer)</td>
<td>CEO/Principal</td>
<td>LEMAX, LLC</td>
</tr>
<tr>
<td>Anne S. Lindblad</td>
<td>President &amp; CEO</td>
<td>The Emmes Corporation</td>
</tr>
<tr>
<td>Joel Marcus</td>
<td>Executive Chairman &amp; Founder</td>
<td>Alexandria Real Estate Equities</td>
</tr>
<tr>
<td>Charles Morton (Secretary)</td>
<td>Partner</td>
<td>Venable, LLP</td>
</tr>
<tr>
<td>Sara Nayeem</td>
<td>General Partner, New Enterprise Associate</td>
<td>NEA</td>
</tr>
<tr>
<td>Kurt Newman, M.D.</td>
<td>President &amp; CEO</td>
<td>Children’s National Medical Center</td>
</tr>
<tr>
<td>Dr. Jay Perman</td>
<td>Chancellor</td>
<td>University System of Maryland</td>
</tr>
<tr>
<td>Nanakumar Deorak (INTERIM)</td>
<td>Vice President</td>
<td>Avantor</td>
</tr>
<tr>
<td>Aaron Ren</td>
<td>Head of BD &amp; Operations</td>
<td>Viela Bio</td>
</tr>
<tr>
<td>John A. Sackett</td>
<td>President</td>
<td>Shady Grove Adventist Hospital</td>
</tr>
<tr>
<td>Robert Silverman</td>
<td>Head, External Drug Discovery Partnering, Roche</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Tracey Vetterick</td>
<td>Chief Operating Officer</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>

May 2020
BioHealth Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Healthcare Services
- E-Health
- Mobile Health
- Electronic Medical Records
- Biomarkers and Tools
- Health Informatics
- BioHealth Cybersecurity
- Personalized Health
- Convergence
Innovation Paradigm Shift

PROOF OF CONCEPT
(Technological Feasibility)
Laboratory Push
“It Works!”

PROOF OF COMMERCIAL RELEVANCE
(Market Pull)
“It Works To Solve A Problem”
“I’ll Buy It”
Research and technologies enter into the pipeline from sources shown on the left and are evaluated by the EIR team. Commercially relevant startups are connected to assistance programs on a case-by-case basis. Once a startup becomes a portfolio company, they gain access to partners and resources.
Venture Investment in BHCR is Growing

Total Investment Dollars Near All-time Highs

Capital is Moving Upstream

Several Recent Successful Exits

Data gathered from Pitchbook 2019
BHCR has Many Successful Recent Exits
BioHealth Capital Region

Recent Company Fundraising Successes Located in BHCR

MedImmune/AstraZeneca spin-out
$250M Series A : $75M Series B
$157M IPO Oct-2019

BeneVir
NYU spin-out
$50M raise Q2-19
Acquired by Janssen (JNJ) for $1.04B (2018)

PROTEUS
Johns Hopkins spin-out
$36M raise 2019

NEURALY
$173M raise 2019

IMMUNOMIC
$61.3M raise Q1-20

Thrive.
Johns Hopkins spin-out
$45M raise 2019

sRNAomics
$47M as of 2019

Lifesprout
$28.5M Series A as of 2020

Graybug Vision
Johns Hopkins spin-out
$129M raise Aug-2019

Arillow
Johns Hopkins spin-out
$85M as of Q4-19
Series B

Dracen Pharmaceuticals
Johns Hopkins spin-out
$40M raise 2019

WindMIL Therapeutics
$42.5M raise 2019

NextCure
Technology from Yale
$160M raise 2019
$75M IPO May-2019

BHI Companies

MACROGENICS
$320M raise 2019

PGD
Johns Hopkins spin-out
$99.3M raise 2019

BHI
Aledade
$131M raise 2019

2019 Data gathered from Pitchbook, Crunchbase
BioHealth Capital Regions Serial Entrepreneurs

Mark P. Klein
- Precision for Medicine, Inc.
- United BioSource Corporation
- Infoscriber Corporation
- U.S. BioServices, Inc.

Rachel King
- GlycoMimetics
- NEA
- Genetic Therapy, Inc.

Michael Richman
- NextCure
- Amplimmune

James S. Gammie, MD
- Correx, Inc.
- Harpoon Medical

Ethan D. Leder
- Precision for Medicine, Inc.
- United BioSource Corporation
- U.S. BioServices, Inc.

Martine A. Rothblatt Ph.D., J.D.
- United Therapeutics Corporation
- GeoStar
- SiriusXM Satellite Radio

Murat V. Kalayoglu
- Cartesian Therapeutics
- Topokine Therapeutics
- HealthHonors Corporation

Wendy Perrow
- AsclepiX Therapeutics
- Alba Therapeutics Corporation

Steve Turner
- Protea Biosciences Group, Inc.
- Clinomix BioSciences Inc.
- Quorum Sciences

Anthony Saleh
- miRecule
- Mimetas
- BioHealth Innovation

Peter Greenleaf
- Aurinia
- Cerecor
- Sucampo
- MedImmune
This commercialization model shows the steps and partners that are involved in the BHI commercialization and support process. The process below leads to the creation of new companies, spin-outs and strategic partnerships. BHI connects companies with a network of public, private and academic entities.
NIH Partnership Agreements

NIH Consulting Entrepreneur Services Contract for 6 NIH Entrepreneurs-in-Residence

PIA between BHI and NIH’s Office of Technology Transfer (OTT) that supports the 27 NIH institutes’ $4 billion intramural research and the Food and Drug Administration to promote and foster cooperative research and accelerate technology commercialization among NIH/FDA, businesses, and universities.
### Innovation Capital Valley of Death

<table>
<thead>
<tr>
<th>Stage</th>
<th>POR / Pre-Seed</th>
<th>Seed/Start-Up</th>
<th>Early</th>
<th>Later</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source</td>
<td>Founders, FFF</td>
<td>Angels, IBED, SBIR</td>
<td>Venture Funds</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bootstrapping</td>
<td>Accelerator Seed Funds</td>
<td>M&amp;A, IPO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Crowdfunding</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demand</td>
<td>$0K</td>
<td>$500K</td>
<td>$2M</td>
<td>+$5M</td>
</tr>
</tbody>
</table>

**“Valley of Death”**

Funding Gap
Virtual Investment Conference
October 19 + 21, 2020
at AstraZeneca

INVITATION ONLY

2018
95 Invited Companies
32 Invited Investors

2019
108 Invited Companies
47 Invited Investors

To connect Quality emerging BioHealth companies seeking capital to investors looking for Quality deals.

SPONSORED BY:

Wilson Sensini Goodrich & Rosati
BioHealth Innovation
J.P. Morgan

For more information contact: BHI@BioHealthInnovation.org
BioHealth Capital FUND

Fund Intends to Address Critical Gap in Current Funding Portfolios

Investment Size

$100K $500K $1M $5M $10M $25M+

BioHealth Capital Fund
Affiliate of BHI

New Enterprise Associates
#2 Most Active Investor

BroadOak
ArrowMark Partners
Green Spring Associates
Northpond Ventures

- BHI’s Own Analysis
- Funds located in Capital Region

Dingman Center Angels
Maryland Momentum Fund
TEDCO
CIT GAP BioLife Fund
Baltimore Angels
Camden Partners
Alexandria Real Estate Equities
#1 Most Active Investor

©2020 BHI
COVID-19 Pandemic

There has never been a better time to invest in biohealth than NOW!
BioHealth Capital FUND

BHCR is a Top Region for BioHealth Investment in the US

The BioHealth Capital Region companies are attracting more top tier investors

**Seattle, WA**
- #9 Region
- $372 million Invested
- 21 Deals

**San Francisco, CA**
- #2 Region
- $6.06 billion Invested
- 156 Deals

**Los Angeles, CA**
- #7 Region
- $221 million Invested
- 21 Deals

**San Diego, CA**
- #5 Region
- $1.10 billion Invested
- 52 Deals

**Chicago, IL**
- #10 Region
- $332 million Invested
- 9 Deals

**Boston, MA**
- #1 Region
- $6.16 billion Invested
- 156 Deals

**New York, NY**
- #3 Region
- $1.08 billion Invested
- 40 Deals

**Philadelphia**
- #6 Region
- $773 million Invested
- 22 Deals

**Research Triangle, NC**
- #8 Region
- $481 million Invested
- 18 Deals

**BHCR (DC/MD/VA)**
- #4 Region
- $944 million Invested
- 44 Deals

2019/9/23 Data gathered from Genetic Engineering News
[https://www.genengnews.com/a-lists/top-10-u-s-biopharma-clusters-7/](https://www.genengnews.com/a-lists/top-10-u-s-biopharma-clusters-7/)
BioHealth Capital FUND

BioHealth Activity

Pharma & Biotech account for annual avg. of 7% of total deal # & 13% of total VC $
<table>
<thead>
<tr>
<th><strong>Name</strong></th>
<th>BioHealth Capital Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lead Investor</strong></td>
<td>Alexandria Real Estate Equities (ARE)</td>
</tr>
<tr>
<td><strong>Structure</strong></td>
<td>Delaware Limited Partnership</td>
</tr>
<tr>
<td><strong>Target Fund Size</strong></td>
<td>$50m with first close at $25m</td>
</tr>
<tr>
<td><strong>Term</strong></td>
<td>10 years with 2 one-year extension provisions</td>
</tr>
<tr>
<td><strong>Investment Period</strong></td>
<td>5 years from final close date</td>
</tr>
<tr>
<td><strong>Investment Focus</strong></td>
<td>Seed to Series A stage companies in the biohealth industry</td>
</tr>
<tr>
<td><strong>Management Fee</strong></td>
<td>2% of committed capital, declining after investment period, payable quarterly</td>
</tr>
<tr>
<td><strong>Carried Interest</strong></td>
<td>20%</td>
</tr>
<tr>
<td><strong>Minimum Unit</strong></td>
<td>$1M LP : HNW By Invite Only</td>
</tr>
</tbody>
</table>
Strong track record of generating returns on BioHealth innovation

Investment Team

Rich Bendis
Fund Manager
Founder & CEO, BioHealth Innovation
40+ years c-level experience in tech & biohealth company management, investment, capital formation, and entrepreneurship

Andrea Alms
Fund Manager
Experienced venture capital and private equity professional

BHI Team has Deep Portfolio and Commercialization Experience

Lynne Brisbane
Director of Finance

John Sullivan, MBA
Previous Experience: Boston Sci. Cardinal Health, Foundation Medical Partners VC

Anthony Saleh, Ph.D.
Previous Experience: Mirecule, Mimetas, NCI

Stephen Wolpe, Ph.D.
Previous Experience: Wellstat, TailRx US

Albine Martin, Ph.D.
Previous Experience: Life Tech, Neogenix Oncology, Precision Biologics

Luis Gutierrez, Ph.D.
Previous Experience: Covance, Aptiv Solutions, Theranostics Health

Ethel Rubin, Ph.D.
Previous Experience: Medtronic, Biofortis, CSA Medical

Judy Costello
Managing Director, Economic Development

Anthony Saleh, Ph.D.
Previous Experience: Mirecule, Mimetas, NCI

Stephen Wolpe, Ph.D.
Previous Experience: Wellstat, TailRx US

Albine Martin, Ph.D.
Previous Experience: Life Tech, Neogenix Oncology, Precision Biologics

Luis Gutierrez, Ph.D.
Previous Experience: Covance, Aptiv Solutions, Theranostics Health

Salman Hasan Ph.D.

Feng Tao, Ph.D.

Rini Pek, Ph.D.

Ashwin Kulkarni, MS

Delphine Lissa, Pharm.D.,Ph.D.
BHI Federal Funding Assistance

- $3.5 billion annual United States Government program coordinated by the Small Business Administration provides grants or contracts to small businesses to spur technological innovation
- Grants awarded in 3 phases between $100,000 and $2.0 million
- Non-dilutive

Value Chain of Assistance

- Funding Concept Review
  Ensure Appropriateness for the Federal Agency

- Application Technical Support
  Guidance through Federal Registration Process

- Proposal Development
  In-Kind Guidance on Proposal Best Practices

- Funding for High-Quality Proposals
  Intensive Support with Professional Consultant

Funding Agencies

$34M Funding awarded | 51 wins of 115 SBIR and STTR submissions | 53% success rate
LaunchLab I

FEATURES
- Five laboratory/office modules; each approximately 1,200 Rentable Square Feet (RSF)
- Laboratory space includes casework, sink, fume hood, equipment storage, emergency generator capacity, etc.
- Office space includes one furnished office, two workstations and common lobby, pantry, conference rooms, IT closet, autoclave, and glass wash so business can immediately commence.

LEASE TERMS
- 12 month lease terms with potential for a six (6) month extension
- Base Rent is $3,925 per month to account for rent and operating expenses inclusive of utilities
- Security deposit is equivalent to one (1) month of Base Rent

Resident Companies include 3i Diagnostics & Antidote Therapeutics

708 Quince Orchard Road | Gaithersburg, MD 20876
- Business accelerator for health startups in 2015
- 5 month formal co-working program with 7 month continuation
- Connect founders with a strong mentor network
- Help founders grow into a company ready for pilot testing and
- Cohort of 7 companies and their founders recruited globally
- Up to $50,000 in stipends per company
- Product focus
- Software developer pool
- Long term support/transition into Montgomery County Incubator Network
- Close proximity to NIH, FDA, HHS, Health companies, international trade representatives and BioHealth Innovation
- **Program Duration: October 2015 – March 2016**

---

Agewell are developing a data analytics tool which can use the accelerometers in modern devices (cell phones, wearables etc) to determine risk of falling among seniors.

CheeksUp are developing a system to support speech children receiving speech and language support.

Ergonometrix are developing a wearable device which can determine the risk of back injury.

Gastro Girl is a name of a popular blog focused on the community of patients living with GI conditions such as Crohn’s, IBS etc. The founders are developing a technology platform focused on delivering health coaching and support to the GI community.

Lazy are developing a product to automate and streamline the collection and submission of key quality metrics by hospitals and other health providers.

The team at Neopenda are developing a monitor to measure neonatal vitals with engineered hats for use in the developing world.

The team at Werbie are developing a mobile and web application focused on the dietary needs of women managing high risk pregnancies.
- Health IT accelerator
- Intensive 16 week program for companies and entrepreneurs.
- Participants receive access to a network of business, marketing and product development mentors.
- Retain promising high growth in Maryland
GERMANTOWN INNOVATION CENTER

20271 Goldenrod Lane, Germantown, MD 20876
Montgomery County Innovation Network Facility
Managed by BioHealth Innovation, Inc. (BHI)

49 Private Offices and Office Suites | 12 Wet labs | 32,000 square feet

Features:
▪ Turnkey office space with fully fitted wet labs, including RO water, emergency power, and fume hoods. Located in the heart of the new Pinkney Innovation Complex at Montgomery College (PIC-MC).
▪ Flexible one-year lease agreements with 60-day notice terms.
▪ Shared conference rooms with state-of-the-art audio visual systems, pre-wired offices to accommodate both telephone and broadband internet service, and wireless internet access.
▪ On-site access to market research databases provided through partnership with TEDCO to bona fide entrepreneurs and faculty innovators.
▪ Access to interns, faculty and state-of-art equipment at BioScience Education Center, Montgomery College

22 Companies | 101 Jobs

<table>
<thead>
<tr>
<th>Therapeutics</th>
<th>Diagnostics &amp; Research Tools</th>
<th>Health Tech</th>
<th>Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arcellx</td>
<td>Leads Biolabs</td>
<td>ClinicMax</td>
<td>IFT</td>
</tr>
<tr>
<td>Medytox</td>
<td>AcouSort</td>
<td>Four Gates LLC</td>
<td>SERVEFED MD</td>
</tr>
<tr>
<td>seraxis</td>
<td>Adera Labs</td>
<td>epigenomics</td>
<td></td>
</tr>
<tr>
<td>BIOnecure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>orogenesis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Theraly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuraly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akan Biosciences</td>
<td>Zalgen Labs</td>
<td>3iDx</td>
<td></td>
</tr>
<tr>
<td>NuSep</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
BHI INTERNATIONAL SOFT-LANDING PROGRAM

• U.S Subsidiary/Corporation Creation
• Business Development and Market Analysis
• Grant Funding/Non-Dilutive Funding Assistance
• Human Resource and General Administration Support
• Marketing and Promotion
• Pricing and Reimbursement
• Regulatory
• Resource Identification
BHI International Soft Landing

BHI offers international companies the perfect starting point to create US-based subsidiaries. Soft landing companies are given access to BHI’s extensive business resources including Business Development & Sales, Entrepreneurs-in-Residence (EIR), Financial, Grant Writing/SBIR Federal Funding Assistance, Human Resources, Incubation/Site Location, Legal - Corporate & Intellectual Property, Marketing & Promotion, Market Research, Network & Connections, Regulatory & Preclinical/ Clinical, and Reimbursement.
**Websites, News and More**

**BHI Website**

The BHI website has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

[www.biohealthinnovation.org](http://www.biohealthinnovation.org)

**BioHealth Capital Region**

The BHCR website highlights the region's biohealth news, stories, trends and events.

[www.biohealthcapital.com](http://www.biohealthcapital.com)

**BioTalk**

Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry.

**BHI News**

BHI's weekly e-newsletter highlights the Central Maryland region's news articles, national biohealth trends and feature stories.

[www.biohealthinnovation.org/news](http://www.biohealthinnovation.org/news)

**BHCR News**

BHCR News is a monthly publication that highlights industry news throughout the region.
BioHealth Innovation, Inc. (BHI) Founder, President & CEO, Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry. BioTalk enables you to learn from these leaders about issues which can help you grow your business. What are the current trends? Where are industry sectors headed? How do we increase access to capital in our region? Rich and his guests dive deep into these topics and much more.

Produced by Andy Eckert, with help from The Podcast Consultant, Mathew Passy.

Dan Abdun-Nabi
Emergent BioSolutions, President & CEO

Magaret Anderson
Deloitte Consulting LLP, Managing Director

Rip Ballou, MD
GSK Global Vaccines US, Vice President & Head

Matt Brady
Scheer Partners, Vice President

Chris Frew
Workforce Genetics, Principal & Founder

Jonathan Cohen
20/20 GeneSystems, Founder, President, & CEO

Brian Darmody
UMD Associate VP of Corporate Engagement

George Davis
Maryland TEDCO, CEO

Emily English
Gemstone Therapeutics, CEO

Brian Gaines
MdBio Foundation, CEO

Dr. Andrew Lees
Fina Biosolutions, Chief Scientific Officer & CEO

Ashish Kulkarni
Avantor, Executive VP & Chief Technology Officer

Monica Lopez, PhD
La Petite Noiseuse Productions

Charles J. Andres
Wilson, Sonsini, Goodrich & Rosati, Associate

Dr. William E. Bentley
Fischell Institute, Founding Director

Jeff Gallagher
Virginia Bio, CEO

Jeff Galvin
American Gene Therapeutics, Founder & CEO

Angela Graham
Quality Biological, President & CEO

Todd Haim
NIH

Bill Hearl
Immunomic Therapeutics, Founder & CEO

Jim Hughes
University of Maryland Baltimore

Tami Howie
Maryland Tech Council, CEO

Jim Jackson
Emergent BioSolutions

Rachel King
GlycoMimetics, Co-Founder & CEO

Dr. Anne Lindblad
GlycoMimetics, Co-Founder & CEO

Douglas Liu
QIAGEN, Senior Vice President Global Operations

Matthew McMahlon
NIH

Matt Mulvey
BeneVir, Co-Founder & CEO

Kurt Newman, MD
Children’s National Health System, President & CEO

Dr. Jay Perman, MD
University of Maryland Baltimore, President

David Petr
MCEDC, CEO

Lily Qi
Montgomery County, Assistant Chief Administrative Officer

Christy Wyskiel
JHU, Senior Advisor to the President

Dr. Crystal Icenhour
Aperiomics, CEO

Dr. Julia Finkel
Children’s National Medical Center, Pediatric Anesthesiologist

Laurie Strongin
Hoper for Henry Foundation, CEO

Dr. Srujana Cherukui
Noble Life Sciences, CEO

John Trainer
AstraZeneca, Vice President & Head, Partnering & Strategy
**BHI: The Triple Bottom Line**

Grows high-paying jobs and businesses

Expands tax base; improves economic vitality

...and benefits human health!
BHI Contact

1 Church Street, Suite 801
Rockville, MD 20850
(301) 637-7950

info@biohealthinnovation.org

www.biohealthinnovation.org